Axplora Consolidates Global UDCA API Manufacturing at India's Vizag Facility After European Exit

A site transfer of this scale carries regulatory weight well before the first batch ships: Axplora has completed the consolidation of its global ursodeoxycholic acid (UDCA) API manufacturing at its Visakhapatnam (Vizag) facility in India, retiring production at its legacy Italian site. For QA directors and regulatory affairs leads managing supplier qualification files, the move triggers a mandatory assessment of site-change notifications under 21 CFR Part 314 and the corresponding ICH Q7 active pharmaceutical ingredient GMP framework.

The strategic rationale is straightforward: Vizag offers higher throughput capacity and a lower cost base than the European operation, while positioning Axplora to serve a UDCA market that continues to expand across hepatology and gastroenterology indications. Consolidating to a single global site eliminates dual-site inventory complexity but concentrates supply risk, a trade-off that procurement and supply-chain leads at finished-dose manufacturers will need to model against their safety stock assumptions.

From a process validation standpoint, transferring a bile-acid API from one GMP-certified site to another requires full revalidation of critical process parameters and analytical methods, with comparability data submitted to each regulatory jurisdiction holding a marketing authorisation that references the Italian site. The number of affected dossiers across the EU, US, and other ICH markets will determine the administrative timeline before customers can draw from Vizag-sourced material against existing approvals.

Axplora has cited sustainability improvements as an additional output of the consolidation, though the company has not published specific metrics on solvent recovery rates or energy intensity reductions at Vizag relative to the Italian baseline. Plant heads evaluating the site as a qualified supplier will likely request environmental and EHS performance data as part of their audit packages.

The Vizag facility's existing GMP standing and its track record in complex API synthesis provide a credible regulatory foundation for the transfer, but the pace at which affected marketing authorisation holders complete their variation filings will set the practical timeline for full commercial supply from the consolidated site.

Source: Media4Growth via Indian Pharma Post, 9 June 2026.